Hidradenitis suppurativa responding to treatment with infliximab

Australasian Journal of Dermatology

Volumn 51, Issue 3, 2010, Pages 186-190

  Lasocki, Anita ^a   Sinclair, Rodney ^b,c   Foley, Peter ^b,c,d   Saunders, Helen ^b,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d SKIN AND CANCER FOUNDATION   (Australia)

Author keywords

anti tumour necrosis factor monoclonal antibody; biologic

Indexed keywords

INFLIXIMAB;

ADULT; ARTICLE; CASE REPORT; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAINTENANCE THERAPY; MALE; RELAPSE; SCORING SYSTEM; SUPPURATIVE HIDRADENITIS; TREATMENT RESPONSE; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77955294339     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2010.00623.x     Document Type: Article

References (11)

1. Wolkenstein P, Loundou A, Barrau K et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J. Am. Acad. Dermatol. 2007 56 : 621 623.
2. von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br. J. Dermatol. 2001 144 : 809 813.
3. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J. Am. Acad. Dermatol. 2009 60 : 539 561.
4. Kurzen H, Kurokawa I, Jemec GB et al. What causes hidradenitis suppurativa? Exp. Dermatol. 2008 17 : 455 472.
5. Attanoos RL, Appleton MA, Douglas-Jones AG. The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br. J. Dermatol. 1995 133 : 254 258.
6. Mandal A, Watson J. Experience with different treatment modules in hidradenitis suppurativa: a study of 106 cases. Surgeon 2005 3 : 23 6.
7. Martinez F, Nos P, Benlloch S et al. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm. Bowel. Dis. 2001 7 : 323 326.
8. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br. J. Dermatol. 2008 158 : 567 572.
9. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br. J. Dermatol. 2008 158 : 370 374.
10. Sartorius K, Lapins J, Emtestam L et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br. J. Dermatol. 2003 149 : 211 213.
11. Fardet L, Dupuy A, Kerob D et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J. Am. Acad. Dermatol. 2007 56 : 624 628.